Disseminated Chickenpox Following Live Varicella Vaccination in a Crohn's Disease Patient on Combination Immunosuppression

Overview

Journal Case Rep Gastrointest Med

Publisher Wiley

Date 2025 Jan 28

PMID 39872708

Authors

Quintin Solano

Sarah Uttal

Peter D R Higgins

Jeffrey A Berinstein

Affiliations

Soon will be listed here.

Abstract

Novel therapeutics used in the treatment of inflammatory bowel disease pose an increased risk of viral reactivation in patients. We present a case of a patient with refractory Crohn's disease (CD) who developed primary varicella (chickenpox) of a vaccine-viral strain after receiving combination immunosuppression with high-dose corticosteroids, tumor necrosis factor inhibitor (TNFi), and a Janus kinase inhibitor (JAKi) in the hospital. While this patient recovered and did not experience long term adverse effects, her case provides an opportunity for improvement. To improve safety, healthcare facilities should develop protocols that use electronic medical records enhanced with clinical decision support systems to identify and protect immunocompromised patients from inappropriate live vaccinations.

References

Ghoreschi K, Laurence A, OShea J . Janus kinases in immune cell signaling. Immunol Rev. 2009; 228(1):273-87. PMC: 2782696. DOI: 10.1111/j.1600-065X.2008.00754.x. View

Berinstein J, Aintabi D, Higgins P . In-hospital management of inflammatory bowel disease. Curr Opin Gastroenterol. 2023; 39(4):274-286. PMC: 11227907. DOI: 10.1097/MOG.0000000000000953. View

Berinstein E, Sheehan J, Jacob J, Steiner C, Stidham R, Shannon C . Efficacy and Safety of Dual Targeted Therapy for Partially or Non-responsive Inflammatory Bowel Disease: A Systematic Review of the Literature. Dig Dis Sci. 2023; 68(6):2604-2623. PMC: 9942632. DOI: 10.1007/s10620-023-07837-0. View

Berinstein J, Karl T, Patel A, Dolinger M, Barrett T, Ahmed W . Effectiveness of Upadacitinib for Patients With Acute Severe Ulcerative Colitis: A Multicenter Experience. Am J Gastroenterol. 2024; . PMC: 11427599. DOI: 10.14309/ajg.0000000000002674. View

Farraye F, Melmed G, Lichtenstein G, Kane S . ACG Clinical Guideline: Preventive Care in Inflammatory Bowel Disease. Am J Gastroenterol. 2017; 112(2):241-258. DOI: 10.1038/ajg.2016.537. View

Berinstein J, Sheehan J, Dias M, Berinstein E, Steiner C, Johnson L . Tofacitinib for Biologic-Experienced Hospitalized Patients With Acute Severe Ulcerative Colitis: A Retrospective Case-Control Study. Clin Gastroenterol Hepatol. 2021; 19(10):2112-2120.e1. PMC: 8760630. DOI: 10.1016/j.cgh.2021.05.038. View

Sandborn W, Panes J, DHaens G, Sands B, Su C, Moscariello M . Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials. Clin Gastroenterol Hepatol. 2018; 17(8):1541-1550. DOI: 10.1016/j.cgh.2018.11.035. View

Colombel J . Herpes Zoster in Patients Receiving JAK Inhibitors For Ulcerative Colitis: Mechanism, Epidemiology, Management, and Prevention. Inflamm Bowel Dis. 2018; 24(10):2173-2182. PMC: 6140435. DOI: 10.1093/ibd/izy150. View

Galea S, Sweet A, Beninger P, Steinberg S, LaRussa P, Gershon A . The safety profile of varicella vaccine: a 10-year review. J Infect Dis. 2008; 197 Suppl 2:S165-9. DOI: 10.1086/522125. View

10.

Moro P, Leung J, Marquez P, Kim Y, Wei S, Su J . Safety Surveillance of Varicella Vaccines in the Vaccine Adverse Event Reporting System, United States, 2006-2020. J Infect Dis. 2022; 226(Suppl 4):S431-S440. PMC: 11692937. DOI: 10.1093/infdis/jiac306. View

11.

Winthrop K, Melmed G, Vermeire S, Long M, Chan G, Pedersen R . Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib. Inflamm Bowel Dis. 2018; 24(10):2258-2265. PMC: 6140434. DOI: 10.1093/ibd/izy131. View

12.

Curtis J, Cofield S, Bridges Jr S, Bassler J, Deodhar A, Ford T . The Safety and Immunologic Effectiveness of the Live Varicella-Zoster Vaccine in Patients Receiving Tumor Necrosis Factor Inhibitor Therapy : A Randomized Controlled Trial. Ann Intern Med. 2021; 174(11):1510-1518. DOI: 10.7326/M20-6928. View

13.

Rubin L, Levin M, Ljungman P, Davies E, Avery R, Tomblyn M . 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014; 58(3):309-18. DOI: 10.1093/cid/cit816. View

14.

Sunzini F, McInnes I, Siebert S . JAK inhibitors and infections risk: focus on herpes zoster. Ther Adv Musculoskelet Dis. 2020; 12:1759720X20936059. PMC: 7328488. DOI: 10.1177/1759720X20936059. View